GW, Zowall H, Howlett J,
N-Terminal Pro–B-Type Natriuretic Peptide Testing Improves
the Management of Patients With Suspected Acute Heart Failure:
primary results of the Canadian multicenter IMPROVE-CHF Study. American
Hear Association's Scientific Sessions 2006, November 12-15, 2006,
H. Cost effectiveness in health care: case of HIV in developing
countries. John Deutsch International Executive Program, Program
on Investment Appraisal and Risk Analysis, July, 2006, Queen’s
University, Kingston, Ontario.
EJ, Gaudreault M, Brewer C, Mandalia S, Zowall H,
Gilmore N, Klein M, Lalonde R, Murphy T, Piche, A, Platt R, Roy
J, de la Sablonniere, Hankins C. Cost-effectiveness of HAART in
Quebec , 1991-2001. XV International AIDS Conference, 11-16 July,
2004, Bangkok, Thailand..
SA, Zowall H, Brewer C, Gilmore, Mukherjee J. Highly
active antiretroviral therapy (HAART) for HIV infections and dyslipidemia
: Estimating the impact of nelfinavir and atazanavir on cardiovascular
(CVD) risk and life expectancy (LE) after adjustment for HIV related
mortality. 4th Scientific Forum on Quality of Care and Outcomes
Research in Cardiovascular Disease and Stroke, October 13-14, 2002,
SA, Brewer C, Coupal L, Zowall H, Pradhan A. Estimating
the benefits of
Antihypertensive therapy: an assessment of pressure. International
Pharmacoeconomics & Outcomes Research, (ISPOR), Seventh Annual
International Meeting, 19-22 May 2002, Crystal City, Arlington,
N, Zowall H. Threatening inequality: the struggle
to maintain Canada’s national healthcare system. The 17th
Annual Conference of the Birkbeck Centre for Canadian Studies, The
London Conference for Canadian Studies, and The Aboriginal Circle.
February 23-24 2001, London, UK.
L, Ho V, Lavoie F, Coupal L, Zowall H, Grover SA.
Cost-effectiveness of lipid lowering treatment for the primary and
secondary prevention of cardiovascular disease: a population-based
analysis. Canadian Cardiovascular Society (CCS) Conference, October
2000, Vancouver, BC.
SA, Coupal L, Zowall H, Gomes D, Weiss T, Alexander,
C. How cost-effective is the treatment of dyslipidemia in patients
with diabetes, but without cardiovascular disease? American Diabetes
Association 60th Scientific Sessions, June 9-13, 2000, San Antonio,
L, Coupal L, Zowall H, Grover SA. The cost-effectiveness
of statin therapy to prevent cardiovascular disease: Adjusting for
quality of life. In the proceedings of the 14th Annual Meeting International
Society of Technology Assessment in Health Care. 1998.
L, Paquet S, Levinton C, Zowall H, Grover SA. Estimating
the benefits of Simvastatin in the primary and secondary prevention
of cardiovascular disease. Presented at the Fourth International
Conference on Preventive Cardiology, 1997, Montreal, Quebec, Canada.
AE, Levinton C, Joseph L, Zowall H, Grover SA,
Penrod J, Sibley J, Esdaile JM. Predicting short term direct medical
costs (DC) incurred in RA. Presented at the National Scientific
Meeting of the American College of Rheumatology, November 8, 1996,
H et al. Discussion Panel. 1996 Cardiology Challenges in
Geriatrics, sponsored by Ottawa General Hospital and Hoechst Marion
Roussel Canada Inc., Ottawa, Ontario, October 4, 1996.
H, Coupal L, Grover SA. Estimating the health care costs
of coronary heart disease (CHD) in Canada. Presented at the International
Heart Health Conference, 1992, Vancouver, British Columbia.
H, Coupal L, Fraser RD, Gilmore N, Deutsch A, Grover SA.
A comparison of the economic impact of HIV infection and coronary
heart disease (CHD) among immigrants to Canada. Presented at the
Seventh International Conference on AIDS, 1991, Florence, Italy.
H, Gilmore N, Fraser RD, Deutsch A, Grover SA. HIV screening
among potential immigrants: A cost/benefit analysis. Presented at
the Fifth International Conference on AIDS, 1989, Montreal, Quebec,